Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Cited by (1,006)

Items 801–900 of 1,006

1. ABCB1 Mediates Cabazitaxel–Docetaxel Cross-Resistance in Advanced Prostate Cancer
   Alan Paul Lombard, Chengfei Liu, Cameron M. Armstrong, Vito Cucchiara, Xinwei Gu, Wei Lou, Christopher P. Evans, Allen C. Gao · 2017 · Molecular Cancer Therapeutics
2. Phase III Trials With Docetaxel-Based Combinations for Metastatic Castration-Resistant Prostate Cancer: Time to Learn From Past Experiences
   Emmanuel S. Antonarakis, Mario A. Eisenberger · 2013 · Journal of Clinical Oncology
3. Progress in emerging therapies for advanced prostate cancer
   Stéphane Marie. Oudard · 2012 · Cancer Treatment Reviews
4. Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks
   Michael C. Comiskey, Matthew C. Dallos, Charles G. Drake · 2018 · Current Oncology Reports
5. Impact of the COVID-19 Pandemic on the Urologist’s clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period
   Ariê Carneiro, Marcelo Langer Wroclawski, Bruno Nahar, Andrey Soares, Ana Paula Garcia Cardoso, Nam Jin Kim, Fabrício Rodrigues Torres de Carvalho · 2020 · International braz j urol
6. Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers
   John P. Sfakianos, Jorge Daza, Yang Hu, Harry Anastos, Geoffrey Bryant, Rohan Bareja, Ketan K. Badani, Matthew D. Galsky, Olivier Elemento, Bishoy M. Faltas et al. · 2020 · Nature Communications
7. Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
   Daniel Groener, Cam Tu Nguyen, Justus Baumgarten, Benjamin Bockisch, Karen Davis, Christian Happel, Nicolai Mader, Christina Nguyen Ngoc, Jennifer Wichert, Séverine Banek et al. · 2021 · EJNMMI Research
8. Phase II Trial of Concurrent Sunitinib and Image-Guided Radiotherapy for Oligometastases
   Charles C. L. Tong, Eric C. Ko, Max W. Sung, Jamie A. Cesaretti, Richard G. Stock, Stuart H. Packer, Kevin Forsythe, Eric M. Genden, Myron Schwartz, K. H. Vincent Lau et al. · 2012 · PLoS ONE
9. IN VIVO MODELS OF PROSTATE CANCER METASTASIS TO BONE
   Arun S. Singh, William Douglas Figg · 2005 · The Journal of Urology
10. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
    G. Hudes, S. Tagawa, Y. Whang, M. Qi, X. Qin, T. Puchalski, M. Reddy, M. Cornfeld, M. Eisenberger · 2013 · Investigational new drugs
11. Protopine, a novel microtubule-stabilizing agent, causes mitotic arrest and apoptotic cell death in human hormone-refractory prostate cancer cell lines
    Chun‐Han Chen, Cho-Hwa Liao, Ya-Ling Chang, Jih‐Hwa Guh, Shiow‐Lin Pan, Che‐Ming Teng · 2011 · Cancer Letters
12. Apigenin Sensitizes Prostate Cancer Cells to Apo2L/TRAIL by Targeting Adenine Nucleotide Translocase-2
    Masakatsu Oishi, Yosuke Iizumi, Tomoyuki Taniguchi, Wakana Goi, Tsuneharu Miki, Toshiyuki Sakai · 2013 · PLoS ONE
13. Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs
    Eitan Amir, Boštjan Šeruga, Joaquín Martínez‐López, Ryan C. Kwong, Atanasio Pandiella, Ian F. Tannock, Alberto Ocaña · 2011 · Journal of Clinical Oncology
14. Recent developments in antiandrogens and selective androgen receptor modulators
    Bernard Haendler, Arwed Cleve · 2011 · Molecular and Cellular Endocrinology
15. Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis
    Francesco Massari, Chiara Ciccarese, Anna Caliò, Enrico Munari, Luca Cima, Antonio Benito Porcaro, Giovanni Novella, Walter Artibani, Teodoro Sava, Albino Eccher et al. · 2015 · Targeted Oncology
16. Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications
    Naoki Terada, Shusuke Akamatsu, Takashi Kobayashi, Takahiro Inoue, Osamu Ogawa, Emmanuel S. Antonarakis · 2017 · Therapeutic Advances in Medical Oncology
17. Antineoplastic activity of isoliquiritigenin, a chalcone compound, in androgen-independent human prostate cancer cells linked to G2/M cell cycle arrest and cell apoptosis
    Biyan Zhang, Yun Lai, Yufeng Li, Nan Shu, Zheng Wang, Yanping Wang, Yunsen Li, Zijun Chen · 2017 · European Journal of Pharmacology
18. A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
    Primo N. Lara, Walter Michael Stadler, Jeff Longmate, David I. Quinn, Jason A. Wexler, Marta Van Loan, Przemyslaw W. Twardowski, Paul H. Gumerlock, Nicholas J. Vogelzang, Everett E. Vokes et al. · 2006 · Clinical Cancer Research
19. Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens
    Thall, P. F., Logothetis, C., Pagliaro, L. C., Wen, S., Brown, M. A., Williams, D., Millikan, R. E. · 2007 · JNCI Journal of the National Cancer Institute
20. Overview of the latest treatments for castration-resistant prostate cancer
    Mohamed Bishr, Fred Saad C · 2013 · Nature Reviews Urology
21. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
    Frederik Birkebæk Thomsen, Martin Andreas Røder, Per Rathenborg, Klaus Brasso, Michael Borre, Peter Iversen · 2013 · Scandinavian Journal of Urology
22. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer
    Francesca Vignani, Valentina Bertaglia, Consuelo Buttigliero, Marcello Tucci, Giorgio V. Scagliotti, Massimo Di Maïo · 2016 · Cancer Treatment Reviews
23. Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?
    Shivashankar Damodaran, Christos E. Kyriakopoulos, David Frazier Jarrard · 2017 · Urologic Clinics of North America
24. Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
    Rohan Garje, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, R. Bryan Rumble, Mary‐Ellen Taplin, Terry M. Kungel, Daniel Herchenhorn, Tian Zhang, Kathryn Eby Beckermann, Neha Vapiwala et al. · 2025 · Journal of Clinical Oncology
25. Targeting molecular resistance in castration-resistant prostate cancer
    Thenappan Chandrasekar, Joy C. Yang, Allen C. Gao, Christopher P. Evans · 2015 · BMC Medicine
26. Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells
    Jason A. Sprowl, Kerry Reed, Stephen Armstrong, Carita Lannér, Baoqing Guo, Irina Kalatskaya, Lincoln David Stein, Stacey L. Hembruff, Adam Tam, Amadeo Mark Parissenti · 2012 · Breast Cancer Research
27. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: A review
    Emine Elif Özkan · 2011 · Molecular and Cellular Endocrinology
28. Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer
    John J. Kim, Bo Yin, Christhunesa Soundararajan Christudass, Naoki Terada, Krithika Rajagopalan, Ben Fabry, Danielle Y. Lee, Takumi Shiraishi, Robert H. Getzenberg, Robert W. Veltri et al. · 2012 · Journal of Cellular Biochemistry
29. Timing Is Everything: Preclinical Evidence Supporting Simultaneous Rather Than Sequential Chemohormonal Therapy for Prostate Cancer
    Bernhard J. Eigl, Scott E. Eggener, Jenny Baybik, Susan Ettinger, Kim N. Chi, Colleen C. Nelson, Zhou Wang, Martin Edwin Gleave · 2005 · Clinical Cancer Research
30. New research findings on zoledronic acid: Survival, pain, and anti-tumour effects
    Fred Saad C · 2007 · Cancer Treatment Reviews
31. Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis
    Bin Li, Xunbo Jin, Hui-lin MENG, Bo Hu, Tao Zhang, Yu Liang Jiang, Shaoan Chen, Xudong Guo, Weiguo Wang, Wei Jiang et al. · 2017 · Oncotarget
32. Repurposing itraconazole for the treatment of cancer
    Rachel Pounds, Sarah M. Leonard, William O. Dawson, Sean T Kehoe · 2017 · Oncology Letters
33. CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1
    Arun Bhardwaj, Sanjeev K. Srivastava, Seema Singh, Sumit Arora, Nikhil Tyagi, Joel Andrews, Steven B McClellan, James E. Carter, Ajay P. Singh · 2014 · Oncotarget
34. Progress and controversies: Radiation therapy for prostate cancer
    Neil E. Martin, Anthony Victor D'Amico · 2014 · CA A Cancer Journal for Clinicians
35. Guía de la EAU sobre el cáncer de próstata. Parte II: tratamiento del cáncer de próstata avanzado, recidivante y resistente a la castración
    Nicolas Mottet, Joaquim Bellmunt B, M. Bolla, Steven Joniau, Malcolm David Mason, Vsevolod Borisovich Matveev, Hans‐Peter Schmid, Theodorus van der Kwast, Thomas Wiegel, Filiberto Zattoni et al. · 2011 · Actas Urológicas Españolas
36. Systemic treatments for high-risk localized prostate cancer
    G. Pignot, Denis Maillet, Emmanuel Gross, Philippe Barthélémy, Jean‐Baptiste Beauval, Friederike Constans-Schlurmann, Yohann Loriot, Guillaume Ploussard, Paul Sargos, Marc‐Olivier Timsit et al. · 2018 · Nature Reviews Urology
37. AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
    Navid Sobhani, Praveen Kumar Neeli, Alberto D’Angelo, Matteo Pittacolo, Marianna Sirico, Ilaria Camilla Galli, Giandomenico Roviello, Gabriella Nesi · 2021 · International Journal of Molecular Sciences
38. Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
    Hannah L. Rush, L.R. Murphy, Alicia Katherine Morgans, Noel William Clarke, Adrian David Cook, Gerhardt Attard, Archie Macnair, David Paul Dearnaley, Chris C. Parker, J. Martin Russell et al. · 2021 · Journal of Clinical Oncology
39. PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications
    Atish Dipankar Choudhury · 2022 · The Prostate
40. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
    Alejo Rodríguez‐Vida, Simon Chowdhury, Cora Nanette Sternberg, Sarah Maria Rudman, Myria Galazi · 2015 · Drug Design Development and Therapy
41. Structurally flexible triethanolamine-core poly(amidoamine) dendrimers as effective nanovectors to deliver RNAi-based therapeutics
    Xiaoxuan Liu, Cheng Liu, Carlo Vittorio Catapano, Ling Peng, Jiehua Zhou, Palma Rocchi · 2013 · Biotechnology Advances
42. A water‐soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFκB and generating reactive oxygen species
    Rajasubramaniam Shanmugam, Praveen Kusumanchi, Liang Cheng C, Peter Anthony Crooks, Sundar Neelakantan, William Matthews, Harikrishna Nakshatri, Christopher J. Sweeney · 2010 · The Prostate
43. Development of innovative paclitaxel-loaded small PLGA nanoparticles: Study of their antiproliferative activity and their molecular interactions on prostatic cancer cells
    Delphine Le Broc, Rodolphe Carpentier, Emmanuelle Lipka, S. Daher, Claude Vaccher, Didier Betbeder, Christophe Furman · 2013 · International Journal of Pharmaceutics
44. Anthracyclines as effective anticancer drugs
    Janos Nadas, Duxin Sun · 2006 · Expert Opinion on Drug Discovery
45. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics
    Deborah Mukherji, Aurelius Gabriel Omlin, Carmel Jo Pezaro, Ali I. Shamseddine, Johann Sebastian De Bono · 2014 · Cancer and Metastasis Reviews
46. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients
    Stéphane Marie. Oudard, Eugéniu Banu, Florian Scotté, A. Banu, Jacques Médioni, Philippe Beuzeboc, Florence Joly, J-M Ferrero, François Goldwasser, Jean‐Marie Andrieu · 2007 · Annals of Oncology
47. A phase II trial of calcitriol and naproxen in recurrent prostate cancer.
    Sandy Srinivas, David Feldman · 2009 · PubMed
48. RETRACTED: Lipid-oligonucleotide conjugates improve cellular uptake and efficiency of TCTP-antisense in castration-resistant prostate cancer
    Sara Karaki, Sébastien Benizri, Raquel Mejías, Virginie Baylot, Nicolas Branger, Dang Tan Nguyen, Brune Vialet, Khalid Oumzil, Philippe Barthélémy, Palma Rocchi · 2017 · Journal of Controlled Release · Retracted
49. Molecular Alterations in Prostate Carcinomas that Associate with In vivo Exposure to Chemotherapy: Identification of a Cytoprotective Mechanism Involving Growth Differentiation Factor 15
    Chung-Ying Huang, Tomasz M. Beer, Celestia S. Higano, Lawrence D. True, Robert L. Vessella, Paul H. Lange, Mark G. Garzotto, Peter S. Nelson · 2007 · Clinical Cancer Research
50. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
    Ola Bratt A, Michael Häggman, Göran Ahlgren, Örjan Nordle, A Björk, J‐E. Damber · 2009 · British Journal of Cancer
51. mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review
    Cara M. Statz, Sara E. Patterson, Susan M. Mockus · 2016 · Targeted Oncology
52. Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment
    Ioulia Vardaki, Paul Gettys Corn, Emanuela Gentile, Jian H. Song, Namrata Madan, Anh G. Hoang, Nila U. Parikh, Leah Guerra, Yu‐Chen Lee, Song-Chang Lin et al. · 2021 · Clinical Cancer Research
53. Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
    Semini Sumanasuriya, George Seed, Harry Parr, Rossitza Christova, Lorna Pope, Claudia Maria Bertan, Diletta Bianchini, Pasquale Rescigno, Ines Figueiredo, JANE C. GOODALL et al. · 2021 · European Urology
54. Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives
    Ruiz de Porras, Vicenç, Font, Albert, Aytes, Alvaro · 2021 · Cancer Letters
55. 481 CLUSTERIN IS A CRITICAL DOWNSTREAM MEDIATOR OF STRESS-INDUCED YB-1 TRANSACTIVATION IN PROSTATE CANCER
    Masaki Shiota, Amina Zoubeidi, Masafumi Kumano, Eliana Beraldi, Seiji Naito, Colleen C. Nelson, Poul H. B. Sorensen, Martin Edwin Gleave · 2011 · The Journal of Urology
56. Importance of ABCC1 for cancer therapy and prognosis
    Tereza Kunická, Pavel Souček · 2014 · Drug Metabolism Reviews
57. Phase II Clinical Trial of Docetaxel in Refractory Squamous Cell Carcinoma of the Cervix
    Agustin A. García, John A. Blessing, Luis Vaccarello, Lynda D. Roman · 2007 · American Journal of Clinical Oncology
58. PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFκB and PPARγ
    Jennifer Hirsch, Christina L. Johnson, Thomas Nelius, Ronald C. Kennedy, Werner T. W. de Riese, Stéphanie Filleur · 2011 · Cytokine
59. Angiogenesis inhibitors in the treatment of prostate cancer
    Clara Hwang, Elisabeth I. Heath · 2010 · Journal of Hematology & Oncology
60. Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02
    Seth A. Rosenthal, Kyoungwha Bae, Kenneth J. Pienta, Mark L. Sobczak, Sucha O. Asbell, Raghu Rajan, Kevin J. Kerlin, Jeff M. Michalski, Howard Mark Sandler · 2008 · International Journal of Radiation Oncology*Biology*Physics
61. Expression profiling of CD133+ and CD133— epithelial cells from human prostate
    Christopher J. Shepherd, S. Rizzo, I. Ledaki, M. Davies, D. Brewer, G. Attard, J. de Bono, D. Hudson · 2008 · The Prostate
62. Overall Survival: Patient Outcome, Therapeutic Objective, Clinical Trial End Point, or Public Health Measure?
    Everardo Delforge Saad, Marc E Buyse · 2012 · Journal of Clinical Oncology
63. The postchemotherapy PSA surge syndrome
    Rodolphe Thuret, Christophe Massard, Marine Gross‐Goupil, Bernard J. Escudier, Mario Di Palma, Alberto Bossi, R. de Crevoisier, Anne Chauchereau, Karim S. Fizazi · 2008 · Annals of Oncology
64. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer
    Gwénaëlle Gravis, Franck Bladou, Naji Salem, Anthony Gonçalvès, Benjamin Esterni, Jochen Christoph Walz, Sophie Bagattini, Myriam Marcy, Serge Brunelle, Patrice Viens · 2008 · Annals of Oncology
65. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond
    Mari Nakazawa, Natasha Kyprianou · 2016 · The Journal of Steroid Biochemistry and Molecular Biology
66. Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis
    Julia Wilkerson, Kald A. Abdallah, Charles Hugh-Jones, Greg Curt, Mace L. Rothenberg, Ronit Simantov, Martin Murphy, Joseph Morrell, Joel Beetsch, Daniel J. Sargent et al. · 2016 · The Lancet Oncology
67. ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass
    Rafael Barreto, Yukiko Kitase, Tsutomu Matsumoto, Fabrizio Pin, Kyra C. Colston, Katherine E. Couch, Thomas M. O’Connell, Marion Everett Couch, Lynda Faye Bonewald, Andrea Bonetto · 2017 · Scientific Reports
68. Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells
    Thomas W. Flaig, Lih‐Jen Su, Gail S. Harrison, Rajesh Agarwal, Leonard Michael Glodé · 2007 · International Journal of Cancer
69. Functionalized gold nanoparticles for drug delivery applications
    S. Thambiraj, S. Hema, Dhesingh Ravi Shankaran · 2018 · Materials Today Proceedings
70. Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden
    Markus Aly, Amy Levál, Frida Schain, Johan Liwing, Joe Lawson, Emese Vágó, Tobias Nordström, Therése Andersson, Erik Sjöland, Chen Wang et al. · 2020 · Scandinavian Journal of Urology
71. Recent advances and future perspectives in the therapeutics of prostate cancer
    Ganji Lakshmi Varaprasad, Vivek Gupta, Kiran Prasad, Eunsu Kim, Mandava Bhuvan Tej, Pratik Mohanty, Henu Kumar Verma, Ganji Seeta Rama Raju, Lakkakula VKS Bhaskar, Yun Suk Huh · 2023 · Experimental Hematology and Oncology
72. Drug Insight: use of docetaxel in prostate and urothelial cancers
    Niklas J. Mackler, Kenneth J. Pienta · 2005 · Nature Clinical Practice Urology
73. Enoxacin inhibits growth of prostate cancer cells and effectively restores microRNA processing
    Elsa Sousa, Inês C. R. Graça, Tiago Baptista, Filipa Quintela Vieira, Carlos Palmeira, Rui Henrique, Cármen Jerónimo · 2013 · Epigenetics
74. Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways
    Su Jung Oh, Holger H.H. Erb, Alfred Hobisch, Frederic Romain Santer, Zoran Čulig · 2012 · Endocrine Related Cancer
75. Surgical management of prostate cancer metastatic to the spine
    Brian J. Williams, Benjamin D. Fox, Daniel Michael Sciubba, Dima Suki, Shi Ming Tu, Deborah Ann Kuban, Ziya Levent Gokaslan, Laurence D. Rhines, Ganesh Rao · 2009 · Journal of Neurosurgery Spine
76. Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis
    Noah M. Hahn, Sharon Marsh, William B. Fisher, Robert M. Langdon, Robin T. Zon, Mark Browning, Cynthia S. Johnson, Tiffany Scott-Horton, Lang Li, Howard L. McLeod et al. · 2006 · Clinical Cancer Research
77. Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients
    D Reyes, L Salazar, E Espinoza, Cristián Pereda, Enrique A. Castellón, Raúl Valdevenito, C Huidobro, Marı́a Inés Becker, Álvaro Lladser, Mercedes Natalia López et al. · 2013 · British Journal of Cancer
78. Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?
    Yeona Cho, Jee Suk Chang, Koon Ho Rha, Sung Joon Hong, Young Deuk Choi, Won Sik Ham, Jun Won Kim, Jaeho Cho · 2016 · PLoS ONE
79. Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer
    Kroon, Jan, Kooijman, Sander, Cho, Nam-Joon, Storm, Gert, van der Pluijm, Gabri · 2016 · Trends in Pharmacological Sciences
80. Loss of SLCO1B3 drives taxane resistance in prostate cancer
    Ellen S. de Morrée, René Böttcher, Robert J. van Soest, Ashraf Aghai, Corrina M. de Ridder, Alice A. Gibson, Ron H.J. Mathijssen, Herman Burger, Erik A.C. Wiemer, Alex Sparreboom et al. · 2016 · British Journal of Cancer
81. A review on engineering polymer drug conjugates to improve combination chemotherapy
    Douglas R. Vogus, Vinu Krishnan, Samir Mitragotri · 2017 · Current Opinion in Colloid & Interface Science
82. Effect of FAK inhibitor VS‐6063 (defactinib) on docetaxel efficacy in prostate cancer
    Hui‐Ming Lin, Brian Yong Lee, Lesley E. Castillo, Calan Spielman, Judith Grogan, Nicole K. Yeung, James G. Kench, Phillip D. Stricker, Anne‐Maree Haynes, Margaret M. Centenera et al. · 2018 · The Prostate
83. Graphene oxide-wrapped PEGylated liquid crystalline nanoparticles for effective chemo-photothermal therapy of metastatic prostate cancer cells
    Raj Kumar Thapa, Yu Seok Youn, Jee‐Heon Jeong, Han‐Gon Choi, Chul Soon Yong, Jong Oh Kim · 2016 · Colloids and Surfaces B Biointerfaces
84. TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization
    Yixiang Li, Baotong Zhang, Lingwei Xiang, Siyuan Xia, Ömer Küçük, Xingming Deng, Lawrence Boise, Jin‐Tang Dong · 2020 · Theranostics
85. Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer
    Ismaheel O. Lawal, Alfred Morgenstern, Mariza Vorster, Otto Knoesen, Johncy Mahapane, Khanyisile Hlongwa, Letjie C. Maserumule, Honest Ndlovu, Janet Reed, Gbenga O. Popoola et al. · 2022 · European Journal of Nuclear Medicine and Molecular Imaging
86. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer
    Roberto Petrioli, Anna Ida Fiaschi, Edoardo Francini, Alessandra Pascucci, Guido Francini · 2008 · Cancer Treatment Reviews
87. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease
    Alfredo Berruti, Marco Tucci, Alessandra Mosca, Roberto Tarabuzzi, G. Gorzegno, Carlo Terrone, Federica Vana, Gianni Lamanna, Marco Tampellini, F. Porpiglia et al. · 2005 · British Journal of Cancer
88. Effects of Serum Testosterone Levels After 6 Months of Androgen Deprivation Therapy on the Outcome of Patients With Prostate Cancer
    Valentina Bertaglia, Marcello Tucci, Cristian Fiori, Emiliano Aroasio, Massimiliano Poggio, Consuelo Buttigliero, Susanna Grande, Andrea Saini, F. Porpiglia, Alfredo Berruti · 2013 · Clinical Genitourinary Cancer
89. EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance
    Yuexing Zhang, Douglas E. Linn, Zhenqiu Liu, Jonathan Melamed, Fabio Rocha Fernandes Tavora, Charles Y.F. Young, Angelika M. Burger, Anne W. Hamburger · 2008 · Molecular Cancer Therapeutics
90. A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer
    Andrew J. Armstrong, Patricia A. Creel, James D. Turnbull, Cassandra N. Moore, Tracy A. Jaffe, Sherri T. Haley, William P. Petros, Sarah Yenser, Jon P. Gockerman, Darryl J. Sleep et al. · 2008 · Clinical Cancer Research
91. Liposomal nanomedicines in the treatment of prostate cancer
    Jan Kroon, Josbert M. Metselaar, Gert Storm, Gabri van der Pluijm · 2013 · Cancer Treatment Reviews
92. CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer
    Chong Li, Shengwu Liu, Ruping Yan, Ning Han, Kwok‐Kin Wong, Lei Li · 2016 · Theranostics
93. ERG Cooperates with Androgen Receptor in Regulating Trefoil Factor 3 in Prostate Cancer Disease Progression
    Rickman, David S., Chen, Ying-bei, Banerjee, Samprit, Pan, Yihang, Yu, Jindan, Vuong, Terry, Perner, Sven, Lafargue, Christopher J., Mertz, Kirsten D., Setlur, Sunita R. et al. · 2010 · Neoplasia
94. Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial
    Daniel Peter Petrylak, Raffaele Ratta, Nobuaki Matsubara, Ernesto Pablo Korbenfeld, Rustem Airatovich Gafanov, Loı̈c Mourey, Tilman Todenhöfer, Howard Gurney, Gero Kramer, Andries Marinus Bergman et al. · 2025 · Journal of Clinical Oncology
95. Is there a role for platinum chemotherapy in the treatment of patients with hormone‐refractory prostate cancer?
    William K. Oh, Miah Hiang Tay, Jiaoti Huang · 2006 · Cancer
96. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response
    John Thoms, Alan Dal Pra, Pieter H. Anborgh, Eva N. Christensen, Neil Eric Fleshner, Cynthia M. Ménard, K Chadwick, Michael Milosevic, Charles Catton, Melania Pintilie et al. · 2012 · British Journal of Cancer
97. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
    Daniel W. Bowles, W W Ma, Neil N. Senzer, Julie Renee Brahmer, Alex A. Adjei, Michael A. Davies, Alexander J. Lazar, Alex C. H. Vo, Scott Peterson, Luke N. Walker et al. · 2013 · British Journal of Cancer
98. Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary
    Paul Gustav Kluetz, Yangmin M. Ning, Virginia Ellen Maher, Lijun Zhang, Shenghui W. Tang, Debasis Ghosh, Robeena M. Aziz, Todd R. Palmby, Elimika Pfuma Fletcher, Jeanne Fourie Zirkelbach et al. · 2013 · Clinical Cancer Research
99. Reflections on Medical Oncology: 25 Years of Clinical Trials—Where Have We Come and Where Are We Going?
    Christopher M. Booth, Ian F. Tannock · 2007 · Journal of Clinical Oncology
100. Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC
     Роберто Пили, Mark Andrew Rosenthal, Paul N. Mainwaring, Guy van Hazel, Sandy Srinivas, Robert Dreicer, Sanjay Goel, Joseph W. Leach, Shirley Wong, Peter Clingan · 2010 · Clinical Cancer Research